Company intelligence / Profile preview
Next Generation Gene Therapeutics
Walnut Creek, California, United Statesnggtbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
NGGT has reported positive data for NGGT002 for Phenylketonuria (PKU) with Phase I/II clinical trials initiated in the U.S. and China. Their NGGT001 therapy for Bietti's crystalline corneoretinal dystrophy showed improvement in vision with patients gaining 12.8 ± 3.7 ETDRS letters (equivalent to 2-3 lines on Snellen chart) at 9 months post-treatment in a 2-site investigator-initiated trial.
- Therapeutic areas
- Metabolic DisordersOphthalmologyNeurology
- Modalities
- Gene therapyAAV (Adeno-Associated Virus) vector-based gene therapies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Next Generation Gene Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Next Generation Gene Therapeutics.